ILC Therapeutics has completed a fundraise worth £2.5m.
Led by Eos, Scottish Enterprise, Medical Incubator Japan and Los Angeles-based lawyer and investor Robert Kopple, the money will support the continued pre-clinical development of the firm’s two lead assets – AlfacyteTM and DermacyteTM – as they move towards the clinic.
Read more HERE.
